Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorption and Excretion of ModraDoc006/Ritonavir in Advanced Solid Tumors
NCT05242926Phase 1Withdrawn
- Sponsor
- Modra Pharmaceuticals
- Start
- Oct 2017
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ModraDoc006 in solid tumor, sponsored by Modra Pharmaceuticals. Primary endpoint: Absorption of oral docetaxel at 168 hours. Planned start Oct 2017; status: withdrawn.
02
Drugs
ModraDoc006
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05242926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05242926.